An employee holds capsules for a photograph inside a pharmaceutical plant in Salcette, Goa, India. (Photographer: Dhiraj Singh/Bloomberg)
India’s drugmakers’ performance in the U.S., the biggest market for most, is improving as pricing environment is becoming stable, according to the nation’s fourth-largest pharmaceuticals firm by value.One of the key factors for earnings of Cipla Ltd. and its domestic peers is improving business in the American market, Kedar Upadhye, chief financial officer at the drugmaker, told BloombergQuint’s Niraj Shah in an interview. That’s goi...